Neurobiology of Disease (Mar 2002)
A Presenilin 1 Mutation Associated with Familial Frontotemporal Dementia Inhibits γ-Secretase Cleavage of APP and Notch
- Zareen Amtul,
- Patrick A. Lewis,
- Sian Piper,
- Richard Crook,
- Matt Baker,
- Kirk Findlay,
- Andrew Singleton,
- Marion Hogg,
- Linda Younkin,
- Steven G. Younkin,
- John Hardy,
- Michael Hutton,
- Bradley F. Boeve,
- David Tang-Wai,
- Todd E. Golde
Affiliations
- Zareen Amtul
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Patrick A. Lewis
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Sian Piper
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Richard Crook
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Matt Baker
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Kirk Findlay
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Andrew Singleton
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Marion Hogg
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Linda Younkin
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Steven G. Younkin
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- John Hardy
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Michael Hutton
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Bradley F. Boeve
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- David Tang-Wai
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Todd E. Golde
- Department of Neuroscience and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida, 32224; Department of Neurology and Mayo Alzheimer's Disease Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
- Journal volume & issue
-
Vol. 9,
no. 2
pp. 269 – 273
Abstract
A novel presenilin 1 mutation, insR352, associated with a frontal temporal dementia phenotype has been identified (E. A. Rogaeva et al., 2001, Neurology 57, 621–625). This mutation does not increase Aβ42 levels, but instead acts as dominant negative presenilin, decreasing amyloid β protein (Aβ) production by inhibiting γ-secretase cleavage of the Aβ precursor. The distinct clinical phenotype associated with this mutation suggests that chronic partial inhibition of γ-secretase activity may result in neurodegeneration.